BREAKING: Results of the first 62 patient randomized clinical trial show hydroxychloroquine helps coronavirus patients improve

Over the past two weeks, everyone has been talking about a small study conducted ​in France. The study, which was led by renowned  Dr. Didier Raoult which showed that 100% of patients that received a combination of HCQ and Azithromycin tested negative and were virologically cured within 6 days of treatment. But several scientists and researchers were quick to cast doubt upon his findings because the testing was not carried out in a controlled study and that the results were purely “observational.”

Now for the first time, results of randomized clinical trial show hydroxychloroquine helps coronavirus patients improve, according to research paper posted at medRxiv. According to a new report from NY Times, the malaria drug hydroxychloroquine has helped to speed the recovery of a small number of patients who were mildly ill from the coronavirus. The report was based on the results of a randomized clinical trial posted at medRxiv, an online server for medical articles, before undergoing peer review by other researchers. The study was small and limited to patients who were mildly or moderately ill, not severe cases. By the way, this is the same NY Times that said about a week ago that: “No, These Medicines Cannot Cure Coronavirus”

According to the report, “cough, fever and pneumonia went away faster, and the disease seemed less likely to turn severe in people who received hydroxychloroquine than in a comparison group not given the drug. The authors of the report said that the medication was promising, but that more research was needed to clarify how it might work in treating coronavirus disease and to determine the best way to use it.”

This study, which was supported by the Epidemiological Study of COVID-19 Pneumonia to Science and Technology Department of Hubei Province, aims to evaluate the efficacy of hydroxychloroquine (HCQ) in the treatment of patients with COVID-19.

“From February 4 to February 28, 2020, 62 patients suffering from COVID-19 were diagnosed and admitted to Renmin Hospital of Wuhan University. All participants were randomized in a parallel-group trial, 31 patients were assigned to receive an additional 5-day HCQ (400 mg/d) treatment, Time to clinical recovery (TTCR), clinical characteristics, and radiological results were assessed at baseline and 5 days after treatment to evaluate the effect of HCQ. Key findings: For the 62 COVID-19 patients, 46.8% (29 of 62) were male and 53.2% (33 of 62) were female, the mean age was 44.7 (15.3) years,” the doctors said.

In conclusion, the doctors said: “Despite our small number of cases, the potential of HCQ in the treatment of COVID-19 has been partially confirmed. Considering that there is no better option at present, it is a promising practice to apply HCQ to COVID-19 under reasonable management. However, Large-scale clinical and basic research is still needed to clarify its specific mechanism and to continuously optimize the treatment plan.”

“It’s going to send a ripple of excitement out through the treating community,” said Dr. William Schaffner, an infectious disease expert at Vanderbilt University.

On March 21, U.S. President Donald Trump tweeted about the wonder drug hydroxychloroquine. At the time, he was ridiculed by mainstream media with some went as far as saying the President was giving “false hope” or “misinformation.”Now, the success and effectiveness of hydroxychloroquine as treatment for coronavirus patient can no longer be ignored by the mainstream media.

HYDROXYCHLOROQUINE & AZITHROMYCIN, taken together, have a real chance to be one of the biggest game changers in the history of medicine. The FDA has moved mountains – Thank You! Hopefully they will BOTH (H works better with A, International Journal of Antimicrobial Agents)…..

— Donald J. Trump (@realDonaldTrump) March 21, 2020